Mithrl raised $20 million in a Series A round led by Obvious Ventures to expand its biomedical world model and agentic AI tooling for drug discovery and development acceleration. The company, founded by Vivek Adarsh, says its platform aims to help R&D teams move from idea to IND 50% faster by combining validated biology curated from peer-reviewed research with public and partnered datasets. Mithrl’s second-generation platform includes a proprietary “biomedical world model” and an agentic harness for model routing, token optimization, and content orchestration. The company says its approach restricts reasoning to validated biology—rather than broad open-ended search—reducing compute demands while still producing hypothesis suggestions with source-level traceability. The funding supports development of Mithrl-1 and launches an early access program tied to a September 21 deployment date for the next-generation system. For biotech users, the practical differentiator is described as benchmark performance and reduced token usage versus standard frontier model workflows. In a sector crowded with AI discovery claims, Mithrl’s round signals continued capital flow toward “bounded” AI systems that emphasize citations, confidence scoring, and integration into sponsor environments rather than standalone generative models.